

CURRICULUM VITAE
OREGON HEALTH & SCIENCE UNIVERSITY

NAME Mark G. Garzotto, M.D.

6/12/2008

PRESENT POSITION AND ADDRESS

Academic Rank: Associate Professor
Department/Division: Surgery/Urology and Radiation Medicine
Professional Address: Portland VA Medical Center
3710 SW US Veterans Hosp Rd, Portland, OR 97239

II. EDUCATION

Undergraduate and Graduate (Include Year, Degree, and Institution):

1986- Louisiana State University, Baton Rouge, BS – Cellular & Microbiology

1990- Louisiana State University School of Medicine, MD, New Orleans, LA

Postgraduate: 1990 to 1992-Surgery Resident, University of Florida, Gainesville,

1992-1995-Urology Resident, University of Florida, Gainesville,

1995-1998-Research Fellow, Laboratories of Signal Transduction and Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
PIs: Richard Kolesnick, MD Zvi Fuks, MD

1998-1999-Clinical Urologic Oncology Fellow, Memorial Sloan-Kettering Cancer Center, New York, NY
Chair: Peter T. Scardino, MD

Certification:

American Board of Urology, 2001

Medical Licenses:

New York

Oregon

III. PROFESSIONAL EXPERIENCE

7/1999 to present, Staff Researcher, Portland Veterans Administration Hospital

7/1999 to present, Staff Urologist, Portland Veterans Administration Hospital
 7/1999 to 6/2004, Assistant Professor of Urology, Oregon Health & Science University
 2004 to present, Associate Professor of Urology, Oregon Health & Science University
 2007 to present, Associate Professor of Radiation Medicine, Oregon Health & Science University

Administrative

1999- Director of Urologic Oncology, Portland VA Medical Center
 2000-2002 Member, Pharmacy and Therapeutics Committee, PVAMC
 2000 to 2002 Physician Liaison for PVAMC to ACS Commission on Cancer
 2006-2007 Chairperson, Research and Development Committee, PVAMC
 2007-2008 Chairperson, (2nd term) Research and Development Committee, PVAMC
 2006- 2008 Member, Research Space Committee, PVAMC

IV. SCHOLARSHIP

Area(s) of Research/Scholarly Interest: Prostate cancer, Genitourinary Oncology, Translational research

Grants and Contracts:

Federal (Include Title, Source, PI, Amount Period, and % Effort)

VA Merit Review Grant (Garzotto)	9/2007-8/2011
Pre-operative Statin Therapy versus Placebo in Human Prostate Cancer	
Role: PI	
VA Merit Review (Shannon)	9/2007-8/2011
Genetic Susceptibility, Environment and Prostate Cancer Risk	Effort 2%
Role: Co-I	
PC040506 DoD (Garzotto)	est. 01/04/05- 12/31/07
Department of Defense Prostate Cancer Research Program	Role of Cyclooxygenase
in Prostate Cancer.	
Role: Principal Investigator	effort: 10%
VA Cooperative Studies program #553	1/1/06-5/2015
Chemotherapy after prostatectomy for high-risk prostate cancer: a phase III trial.	
Role: Executive Planning Committee member, Site Principal Investigator	effort: 5%
National Cancer Institute/VAMC CSP 407	7/1999-7/2007
Prostate cancer intervention versus observation trial (PIVOT)	
Role: Site Principal Investigator	effort: 2%
VA - Medical Research (Epidemiology) (Hickam)	10/2002-04/2007
Comorbidities, Patient characteristics, and Outcomes of Prostate Carcinoma	
Role: Co-Investigator	effort: < 2%

PC030386 DoD (Shannon) est. 01/04/03- 2/28/08
Department of Defense Prostate Cancer Research Program
Fish Oil Supplementation and Fatty Acid Synthase Expression in the Prostate: ARCT.
Role: Co-Investigator effort: 2%

SWOG-99045 (Beer) 1/1/99- open
Southwest Oncology Group
Urologic Cancer Outreach Program (UCOP) of the Southwest Oncology Group, OHSU
Role Co-Investigator effort: <2%

SWOG S0000B: Prevention of Cataract and Age-Related Macular Degeneration with Vitamin E and Selenium--SELECT Eye Endpoints (SEE), Phase III Ancillary to S0000--SELECT
eIRB 807
Opened 4/8/05 - still open

S0437: Prostate Cancer Prevention Trial (PCPT) Companion Long-term Follow-up Study for Men Diagnosed with Prostate Cancer
eIRB 1830
Opened 12/8/05 - still open
effort: 2%

RTOG -0521 (Sandler, Garzotto) A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized High, Risk Prostate Cancer
4/2006-4/2016
Role: National SWOG PI

Completed:

1K22CA94973-01A1 (Shannon) 08/25/2003 - 08/01/2006
National Cancer Institute, National Institute of Health
K22 Career Transition Development Award- Diet and Prostate Cancer Risk
Role: Co-Investigator effort: < 5%

VA ARCD (Garzotto) 7/2002-10/2005
VA Advanced Career Development Award
“Cell cycle targeting in prostate cancer cell radio-resistance.”
Role: Principal Investigator effort: 75%

P50 CA89520 (Lange) 3/1/2003-2/28/2005
NIH/SPORE Funds
Phase II study of transdermal estrogen in androgen-independent prostate cancer (AIPC)
Role: Co-Investigator effort: <2%

1R13 CA93317 (Beer) 6/15/01-6/14/03

National Institutes of Health
Oregon Prostate Cancer Conference
Role: Co-investigator

Medical Research Foundation (Hung) 11/1/04 to 10/31/05
"Radioprotection of bowel with phorbol esters:
Role: Co-I

SWOG S0000: Selenium and Vitamin E Cancer Prevention Trial (SELECT) eIRB 842
Opened 4/25/01- closed 6/24/04

American Cancer Society Young Investigator Award 2000-2001
Investigation into the effect of cell cycle arrest on prostate cancer cell radio-resistance.
Principal Investigator

NIH/NCCAM PAR-04-087 (Shannon) 11/2006-10/2009
ECGC and *-3 Fatty Acids Impact on Fatty Acid Synthase Activity in the Prostate Effort: 3%

State and Local (Include Title, Source, PI, Amount Period, and % Effort)

Medical research Foundation of Oregon (OI: Li, Xin) 4/2007 through 3/2008`
"Prostate Cancer Screening and Staging by Dynamic-Contrast-Enhanced Magnetic Resonance
Imaging (DCE-MRI) Pharmacokinetics"
Role: Co-investigator

Completed:

Medical Research Foundation of Oregon
Study of the effect of Androgen Deprivation on prostate cancer radio-resistance.
Role: Principal Investigator

CA69533-05 Oregon Cancer Institute (Shannon) 06/2001 -- 05/2002
Diet and Prostate Cancer Risk Role: Co-Investigator

Other Support (Include Title, Source, PI, Amount Period, and % Effort)

Phase I/II Study of Preoperative Radiation and Docetaxel Activity in High-Risk Localized Prostate
Cancer eIRB 1581 (Sanofi-Aventis #IIT 16179) 11/05-11/09
Role: P.I. effort: 10%

Aventis (Montgomery): Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent
Prostate Carcinoma, a Phase II Trial Opened 10/23/03 - still open at
VA Role: Site P.I. Effort: <2%

635-ONC-0509-010 (Beer) 2/1/02-1/31/09 effort: <5%
Pfizer, Inc.
Randomized study of pre-prostatectomy celecoxib or placebo
Role: Co-investigator

GIA16080 (Beer) 4/4/2000-4/3/2009
Aventis Pharmaceuticals Products, Inc.
Phase I/II study of neoadjuvant weekly docetaxel and mitoxantrone prior to prostatectomy in patients with high-risk localized prostate cancer
Role: Co-investigator effort: <5%

Publications/Creative Work:

Peer-reviewed

1. Garzotto M, Newman RC, Cohen MC, Rout R, Grice OD: Closure of laparoscopic trocar sites using a spring loaded needle. *Urology* 45: 310-312, 1995.
2. Garzotto M, Walker RD: Uric acid stone and gastric bladder augmentation. *J Urol* 153: 1976, 1995.
3. Narayan P, Tewari A, Garzotto M, Parramore HW, Starling J, Jones T: Transurethral electroevaporation of the prostate: physical principles, technique and results. *Urology* 47: 505-510, 1996.
4. Narayan P, Tewari A, Croker B, Garzotto M, Mustafa S, Jones T, Perinchery G: Factors affecting size and configuration of electroevaporation lesions in the prostate. *Urology* 47: 679-688. 1996.
5. Garzotto M, Tewari A, Wajsman Z: Multimodal therapy for neoplasms arising in a vesical diverticulum. *J Surg Oncology* 62: 46-48, 1996.
6. Furman J, Murphy WM, Jelsma PF, Garzotto M, Marsh RD: Primary primitive neuroectodermal tumor of the kidney. *Am J Clin Path* 106: 339-344, 1996.
7. Garzotto M, Huryk R, Fair WR, Heston WDW: Prostatic tumor implantation in the nude mouse via a perineal approach. *Prostate* 33: 60-63, 1997.
8. Haimovitz A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, Galliliy R, Edwards CK, Schuchman EH, Fuks Z, Kolesnick R: Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. *J Exp Med* 186: 1831-1841, 1997.
9. Garzotto M, Wajsman Z: Neo-adjuvant androgen deprivation combined with salvage surgery for radio-recurrent prostate cancer: Results of 5 year follow-up. *J Urol* 159:950-955, 1998.
10. Garzotto M, White-Jones M, Jiang Y, Lin WC, Haimovitz-Friedman, Fuks Z, Kolesnick R: TPA-induced apoptosis in LNCaP cells is mediated through ceramide synthase. *Cancer Research* 58: 2260-2264, 1998.
11. Garzotto M, Haimovitz-Friedman A, White-Jones M, Huryk R, Heston WDW, Cardon-Cardo C, Kolesnick R, Fuks Z: Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. *Cancer Research* 59: 5195-5201, 1999.
12. Dai J, Shen R, Sumitomo M, Geng Y, Navarro D, Koutcher J, Garzotto M, Powell CT, Nanus DM. Tumor suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells. *Clin Cancer Res* 7(5):1370-7 2001.

13. Garzotto M, Beer T: Syndrome of Inappropriate Anti-Diuretic Hormone Secretion: A Rare Complication of Prostate Cancer. *Journal of Urology* 166:1386, 2001.
14. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, and Henner WD. Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer. *Journal of Clinical Oncology*, 21:123-128, 2003.
15. Beer TM, Garzotto M, Eilers, KM, Lemmon D. Phase II Study of Abarelix-Depot in Androgen-Independent Prostate Cancer Progressing on GnRH Agonist Therapy. *Journal of Urology*, 169:1738-41, 2003.
16. Hoffelt SC, Marshall LM, Garzotto M, Hung A, Holland J, and Beer TM. A Comparison of CT scan to Transrectal Ultrasound-Measured Prostate Volume in Untreated Prostate Cancer. *International Journal of Radiation Oncology Biology Physics* 57: 29-32, 2003.
17. Beer TM, Garzotto M, and Katovic NM. High Dose Calcitriol and Carboplatin in Metastatic Androgen-Independent Prostate Cancer. *Am J Clin Oncol.* 2004 Oct;27(5):535-4.
18. Beer TM, Garzotto M, and Eilers KM. Intermittent Chemotherapy in Metastatic Androgen-Independent Prostate Cancer. *British Journal of Cancer* 89:968-70, 2003.
19. Garzotto M, R. Guy Hudson, Laura Peters, Yi-Ching Hsieh, Eduardo Barrera, Motomi Mori, Tomasz M. Beer, Thomas Klein. Predictive Modeling for the Presence of Prostate Cancer Using Clinical, Laboratory and Ultrasound Parameters in Patients with PSA \leq 10 ng/ml. *Cancer* 98: 1417-1422, 2003.
20. T.M. Beer, M. Garzotto, B.A. Lowe, W.J. Ellis, M.A. Montalto, P.H. Lange, and C.S. Higano. Phase I study of weekly mitoxantrone and docetaxel prior to prostatectomy in patients with high risk localized prostate cancer. *Clin Cancer Res* 10:1306-11, 2004.
21. El-Geneidi M, Garzotto M, Panagiotou I, Hsieh YC, Mori M, Peters L, Klein T, and Beer TM. Delayed Therapy with Curative Intent in a Contemporary Prostate Cancer Watchful Waiting Cohort. *BJU International*, 93:510-5, 2004.
22. Beer TM, Garzotto M, Henner WD, Eilers KM, and Wersinger EM. Multiple Cycles of Intermittent Chemotherapy in Metastatic Androgen-Independent Prostate Cancer. *British Journal of Cancer*, 91: 1425-7, 2004
23. Beer TM, Garzotto M, Eilers KM, and Lemmon D. Phase II Study of Abarelix-Depot in Androgen-Independent Prostate Cancer Progressing after Orchiectomy. *Urology*. 2004 Feb;63(2):342-7.
24. Beer TM, Garzotto M, Eilers KM, and Henner WD. Quality of life during treatment with Calcitriol Enhanced Docetaxel in Metastatic Androgen-Independent Prostate Cancer. *Cancer* 100:758-63.
25. Tiffany NM, Wersinger EM, Garzotto M, Beer TM. Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer. *Urology*. 2004 May;63(5):934-9.
26. Panagiotou I, Hsieh Y-C, Mori M, Peters L, Klein T and Beer TM, Garzotto M. Predictors of Delayed Prostate Cancer-Directed Intervention in Watchful Waiting Patients in the PSA Era. (*Oncology*, (Karger) 67: 194-202, 2004)
27. Garzotto M, Beer TM, Peters L, Klein T, Hsieh Y-C, and Mori M. Improved Detection of Prostate Cancer using Classification and Regression Tree (CART) Analysis. (*J Clin Oncol.* 2005 Jul 1;23(19):4322-9. Epub 2005 Mar 21).
28. Mark Garzotto, Yon Park, Solange Mongoue-Tchokote, Jesse Bledsoe, Laura Peters, Bruce H. Blank, Donald Austin, Tomasz M. Beer, Motomi Mori Recursive Partitioning for Risk Stratification in Men Undergoing Repeat Prostate Biopsies. (*Cancer*. 2005 Nov 1;104(9):1911-7.)

29. Aaron Bayne, John M. Barry and Mark Garzotto. Radical Retropubic Prostatectomy After Orthotopic Liver Transplantation (Urology Jan;65(1):175, 2005)
30. Randomized Study of High-Dose Pulse Calcitriol or Placebo Prior to Radical Prostatectomy. (Cancer Biomarkers Epi Prev 2004 Dec;13(12):2225-32).
31. Daniel M. Janoff, Chad Peterson, Solange Mongoue-Tchokote, Laura Peters, Tomasz M. Beer, Emily M. Wersinger, Motomi Mori, Mark Garzotto: Clinical Outcomes of Androgen Deprivation as Sole Therapy for Localized and Locally Advanced Prostate Cancer (British J Urology Int 2005 Sep;96(4):503-7)
32. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem Biophys Res Commun. 2005 Jul 8;332(3):800-7.
33. Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, Beer TM. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer. 2005 Feb 15;103(4):717-23.
34. Wagner M, Garzotto M, Lemmon D, Eilers KM, Beer TM Prostate-specific antigen decline after gonadotropin-releasing hormone antagonist withdrawal in androgen-independent prostate cancer Urology. 2005 Apr;65(4):799.
35. Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study. J Urol. 2005 Sep;174(3):888-92.
36. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, Farris PE. Statins and prostate cancer risk: a case-control study. Am J Epidemiol. 2005 Aug 15;162(4):318-25.
37. Beer TM, Bland LB, Bussiere JR, Neiss M, Wersinger EM, Garzotto M, Ryan CW, and Janowsky JS. Testosterone loss and estradiol administration modifies memory in men, Journal of Urology, 175(1):130-5, 2006.
38. Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, Beer TM. Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. J Lipid Res. 2006 Feb;47(2):349-55. Epub 2005 Nov 20.
39. Spurgeon SE, Hsieh YC, Rivadinera A, Beer TM, Mori M, Garzotto M. Classification and regression tree analysis for the prediction of aggressive prostate cancer on biopsy. J Urol. 2006 Mar;175(3):918-22
39. Greg Adams, Amanda Mitchell, Ravi Ravichandran, Tomasz M. Beer and Mark Garzotto: Metastatic Adenocarcinoma Of The Prostate In A Healing Sternotomy Site. Urology 68:204, 2006.
40. Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN, Conney AH. Effects of 12-*O*-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3444-51.
41. Beer TM, Garzotto M, Park B, Mori M, Myrthue A, Janeba N, Sauer D, Eilers K. Effect of calcitriol on prostate-specific antigen in vitro and in humans. Clin Cancer Res. 2006 May 1;12(9):2812-6.
42. Beer TM, Bland LB, Bussiere JR, Neiss MB, Wersinger EM, Garzotto M, Ryan CW, Janowsky JS. Testosterone loss and estradiol administration modify memory in men. J Urol. 2006 Jan;175(1):130-5.
43. Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS,

- Trump DL. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. *Cancer Chemother Pharmacol*. 2006 Oct 26.
44. Jennifer Lycette, Lisa Bland, Mark Garzotto, Tomasz M. Beer. Hormonal Therapy for Prostate Cancer: Parenteral Estrogens. *Clin Genitourin Cancer*. 2006 Dec;5(3):198-205.
 45. Stephen E.F. Spurgeon, Solange Mongoue-Tchokote, Lauren Collins, Ryan Priest, Yi-Ching Hsieh, Laura M. Peters, Tomasz M. Beer, Motomi Mori, Mark Garzotto. Assessment of Prostate-Specific Antigen Doubling Time in the Prediction of Prostate Cancer on Needle Biopsy (*Urology* 69:931-5, 2007).
 46. R. Bruce Montgomery, MD, Peter S. Nelson, MD, Daniel Lin, MD, Christopher W. Ryan, MD, Mark Garzotto, MD, Tomasz M. Beer, MD. Diethylstilbestrol and docetaxel; a phase II study of tubulin active agents in patients with metastatic, androgen independent prostate cancer (*Cancer* Jul 18;110(5):996-1002,2007)
 47. J. Graff, M. Mori, H. Li, M. Garzotto, D. Penson, A. Potosky, T. Beer. Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. *J Urol*, Volume 177, Issue 4, Pages 1307-1312.

Non-peer-reviewed

1. Garzotto M, Su SL, Fair WR, Heston WDW: Irradiation-induced apoptosis of human prostate cancer requires cell division: rationale against the use of androgen deprivation with irradiation. *Mol Urol* 1: 227-30, 1997.
2. Garzotto M, Fair WR, Heston WDW: Neo-adjuvant Hormonal Therapy with Radiotherapy for Prostate Cancer: Review of Experimental and Clinical Observations. *Mol Urology* 2:129-133. 1998.
3. Garzotto M, Fair WR: Historical Perspective of Prostate Brachytherapy. *J Endourol* 2000 14(4):315-120, 2000.
4. Garzotto M: Combined androgen deprivation with radiotherapy for prostate cancer: does it make sense? *Mol Urol* 4(3):209-14, 2000.
5. Garzotto M, Nichols CR: Current concepts in risk factor assessment for advanced germ cell cancer. *Seminars in Urologic Oncology*, 19:165-169, 2001.
6. Beer TM, Hough KM, Garzotto M, Lowe BA, and Henner WD. Weekly High Dose Calcitriol and Docetaxel in Advanced Prostate Cancer *Semin Oncol* 2001 Aug;28(4 Suppl 15):49-55.
7. Beer TM, Montalto MA, Lowe BA, and Garzotto M. High-Risk Localized Prostate Cancer Treated with Neoadjuvant Docetaxel and Mitoxantrone. *Case Studies in Prostate Cancer*, 1(2):2-7, 2002.
8. Mark Garzotto. Re: Expression and Cellular Localization of Follicle-Stimulating Hormone Receptor in Normal Human Prostate, Benign Prostatic Hyperplasia and Prostate Cancer *J Urol* 175: 2077, 2006.
9. Mark Garzotto, Anne Myrthue, Celestia S. Higano, and Tomasz M. Beer: Neoadjuvant Mitoxantrone And Docetaxel For High Risk Localized Prostate Cancer. *Urol Oncol*. 2006 May-Jun;24(3):254-9.
10. Mark Garzotto. Re: Pathak et al. Use of testosterone measurements to guide androgen deprivation therapy in prostate cancer. *J Urol*. 2007 Jun;177(6):2135)
11. Garzotto, M. Re: Determining Dosing Intervals for Luteinizing Hormone Releasing Hormone Agonists Based on Serum Testosterone Levels: A Prospective Study. *J Urol* 177:

2135, 2007.

Chapters

1. Garzotto M, Fair WR: "Prostate Cancer" in *Current therapy in Endocrinology and metabolism*, sixth edition (ed. Bardin), Mosby, Philadelphia, 1997, 582-586
2. Garzotto M, Fair WR: "Partial cystectomy and pelvic lymph node dissection" in *Atlas of Surgical techniques in Urology* (ed. Whitehead) Lippincott, Philadelphia, 1998, 167-171
3. Garzotto M, Fair WR: "Outcome Assessment of External Beam Radiotherapy for Clinically Localized Prostate Cancer" in *AUA Update Series* (ed. Ball, et al.) Vol. 19, Chapter 27, 2000.
4. Garzotto M: "The Natural and Treated History of Prostate Cancer" Cambridge Press, 2008 Series: Contemporary Issues in cancer Imaging: Prostate Cancer. Series Editors: Hedvig Hricak and Peter T. Scardino (In Press).